Authored By: Sarah
11 Jul 2024

 Inflammatory Bowel Disease Market Size to grow by USD 7615.7 million between 2024-2028

According to a research report “ Inflammatory Bowel Disease Market” by Distribution Channel (Offline, Online) Type (Crohn's disease, Ulcerative colitis) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 7615.7 million, at a CAGR of  5.48% during the forecast period. The global prevalence of Inflammatory Bowel Diseases (IBD), including ulcerative colitis and Crohn's disease, has witnessed a substantial rise, affecting an estimated 320,000 individuals in Canada in 2023. This number is projected to reach 470,000 by 2035. Factors contributing to this trend include unhealthy diets, sedentary lifestyles, stress, food sensitivities, and bacterial or viral infections. Untreated IBD can lead to debilitating medical complications and significant healthcare expenditures. As a growing health concern, the IBD market represents a substantial business opportunity for pharmaceutical companies and healthcare providers.

Browse market data tables, figures, and in-depth TOC on “Inflammatory Bowel Disease Market” by Distribution Channel (Offline, Online) Type (Crohn's disease, Ulcerative colitis) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Distribution Channel, the Offline segment is projected to dominate the market size in 2024

The Crohn disease segment holds a significant market share in the global Inflammatory Bowel Disease (IBD) market in 2023. This dominance is attributed to the high incidence of Crohn disease among patients. Characterized by inflammation of the digestive tract lining, Crohn disease causes moderate to severe abdominal pain. Corticosteroids, including prednisone and budesonide, are commonly used for short-term symptom relief. The increasing prevalence of Crohn disease is driven by the rising cigarette smoking adoption.

By Type, Crohn's disease  segment is expected to hold the largest market size for the year 2024

Inflammatory Bowel Disease (IBD) market's offline segment remains a vital component, accounting for traditional drug distribution through pharmacies and drugstores. Despite the surge in online distribution channels, the offline channel retains its influence due to consumer preference for immediate availability and personalized pharmacist consultations. This preference benefits pharmaceutical companies, enabling them to expand their consumer reach.

North America is forecasted to hold the largest market size by region in 2024

The Inflammatory Bowel Disease market represents a significant business opportunity due to the rising prevalence of IBD and increasing awareness leading to early diagnosis. Key players are investing in research and development to launch innovative treatments, while strategic collaborations and acquisitions expand their product portfolios. Market growth is driven by these factors, making it an attractive sector for investment.

The Inflammatory Bowel Disease Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Aurobindo Pharma Ltd.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biocon Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson and Johnson Services Inc.
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Inflammatory Bowel Disease (IBD), specifically Crohn's disease and ulcerative colitis, is a significant healthcare concern in industrialized countries. Genetic predisposition and environmental triggers contribute to its prevalence. JAK inhibitors, such as Lilly's Jyseleca and Janus kinase inhibitor, play a crucial role in treating IBD. Ferring Pharmaceuticals and Allergan offer injectable biological drugs like Entyvio and Cimzia, which are effective in managing IBD symptoms. Healthcare systems and institutes in industrialized countries prioritize providing healthcare services for IBD patients, including clinical trials for new treatments. Infections are a common comorbidity in IBD patients, necessitating ongoing research and innovation in the IBD market. Companies like CytoReason employ advanced technologies to analyze patient data and improve treatment outcomes. The Crohn's disease segment of the IBD market continues to grow due to the increasing prevalence and unmet medical needs.

Market Research Overview

The Inflammatory Bowel Disease (IBD) market encompasses various segments, including Ulcerative Colitis and Crohn's Disease. Ulcerative Colitis segment deals with Toll-like Receptor agonists and TNF inhibitors like Skyrizi, Simponi, and Remicade. TNF inhibitors are administered through different routes, including Injectable (e.g., Humira, Entyvio) and Oral (e.g., Jyseleca, Mirikizumab). Telemedicine plays a crucial role in IBD management, enabling remote consultations for healthcare professionals and patients. Moreover, industrialized countries witness a significant disease burden due to IBD, with genetic predisposition and environmental triggers being key factors. Immunosuppressants, such as Janus kinase inhibitors (JAK inhibitors) like Rinvoq, and IL inhibitors, are essential treatments for IBD. Biological drugs, such as Cimzia, are also used extensively. Reimbursement regulations, retail pharmacies, and online pharmacies impact the accessibility and affordability of these treatments. Hospitals and hospital pharmacies are essential healthcare institutes for IBD patients, offering diagnostic techniques like CytoReason for disease detection rates. Clinical trials are ongoing for new treatments, including Allergan's Cimzia and AbbVie's AI-driven therapies.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio